Advanced PCa treatment delays pain progression

Article

Data from a phase III study have linked the advanced prostate cancer drug abiraterone acetate (ZYTIGA) to delayed pain progression and functional decline in a certain subset of advanced prostate cancer patients.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Daniel J. Heidenberg, MD, answers a question during a Zoom video interview
African American patient explaining issues to Asian doctor using tablet | Image Credit: © rocketclips - stockadobe.com
Todd M. Morgan, MD, answers a question during a Zoom video interview
3D illustration of prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.